Cite

HARVARD Citation

    Abou‐Alfa, G. et al. (2020). Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist. pp. e1837-e1845. [Online]. 
  
Back to record